Hearing loss in cystic fibrosis

doi:10.1016/j.ijporl.2010.01.021

International Journal of Pediatric Otorhinolaryngology

Volume 74, Issue 5, May 2010, Pages 469-473

https://doi.org/10.1016/j.ijporl.2010.01.021 Get rights and content

Abstract

Objectives

To verify the prevalence of hearing loss in cystic fibrosis patients and whether the use of aminoglycosides affects hearing and also to analyze whether the distortion product otoacoustic emissions test is suitable to assess sensorineural hearing loss in cystic fibrosis.

Methods

In this descriptive study 120 cystic fibrosis patients aged five months to 18 years were assessed through questionnaires, audiometric tests and analysis of the distortion product otoacoustic emissions. Assessment of previous use of aminoglycosides was performed by collecting data in medical charts.

Results

Audiometric tests show a 4–11% prevalence of sensorineural hearing loss. 89.2% of the patients succeeded in the otoacoustic emissions test, and 42% had used intravenous and/or inhaled aminoglycosides. There was no statistically significant (p = 0.48) relation between the use of aminoglycosides and hearing loss.

Conclusion

Pure tone audiometry and analysis of the distortion product otoacoustic emissions revealed that there was a high prevalence of hearing loss, which makes cystic fibrosis patients a high-risk group which needs periodic assessment by an otorhinolaryngologist. Comparison of the groups with and without aminoglycosides use showed that there was no statistically significant difference among them in analyses, which suggests that the use of aminoglycosides is not the only causal factor for hearing loss in cystic fibrosis.

Introduction

Patients with cystic fibrosis (CF) constitute a group with high use of aminoglycosides (AGS) due to frequent exacerbations of pulmonary infections and chronic colonization by Pseudomonas aeruginosa. Moreover, the used doses of antibiotics are usually high, which may lead to cochlear damage [1]. Clinical assessment of these patients through pure tone audiometry and brainstem evoked response audiometry shows a prevalence of sensorineural hearing loss (SNHL) ranging from 0% to 17% of patients [2], [3], [4], [5], [6], [7], [8], [9], [10], [11]. This variation is related to the type of exam performed and hearing loss criteria, since there is no standard in the literature. Besides that, histopathologic studies in the temporal bone have shown several lesions in the inner ear related to the use of AGS [12], [13], [14]. In the present study, hearing loss was assessed through several methods, with the aim to minimize this lack of standard.

Section snippets

Objectives

The present study aimed to verify the prevalence of SNHL in CF patients using two different methods — pure tone audiometry and distortion product otoacoustic emissions (DPOAE) — and to assess its association with the use of AGS. Also, it aimed to verify whether DPOAE is suitable to assess SNHL in CF patients.

Patients

A 120 CF patients followed at the Cystic Fibrosis Clinic of the Federal University of Minas Gerais General Hospital in order to being assessed in the present study. This sample constitutes 85% of all the population under the age of 18 followed at this unit.

Study design

Patients were assessed through a standardized questionnaire in which were collected data regarding subjective hearing assessment, family history of deafness and factors related to hearing loss such as pre-existing meningitis, premature birth,

General sample characteristics

Mean age of the 120 patients was 8.5 years (SD +4.3), 57% of which were in the 7–14 years age group. Mean age of group 1 (use of ATB) was 7.2 years (SD ±4.8) and group 2 (no use of ATB) was 9.3 years (SD ±4.5). Fifty-six percent were male, 43% were Caucasian, and 83% reported no hearing loss. Causal factors related to SNHL, such as cranial-facial abnormalities and history of previous meningitis were not observed, and in 7.8% of the studied patients, factors such as prematurity (4%), other

Aminoglycosides and ototoxicity assessment

Patients with CF are particularly susceptible to side effects of AGS such as ototoxicity, since they present a higher volume of body distribution and quicker renal clearance, requiring higher doses in order to attain adequate serum concentrations [7].

Despite the frequent use of AGS, few studies have shown hearing loss in CF patients, reporting mild losses at the most. A review of ten studies found in the literature, assessing prospectively or transversally a few dozens of CF patients, showed

Conclusion

Audiometry and analysis of the distortion product otoacoustic emissions revealed that there was a high prevalence of hearing loss in the studied CF patients, which makes this a high-risk group needing periodic assessment by an ENT doctor.

Since CF patients are more exposed to AGS use and due to their ototoxicity, an analysis of whether or not the potential risk of hearing loss is associated to AGS use is indeed imperative. Nevertheless, this analysis showed that, despite the high prevalence,

Acknowledgements

The authors thank the Federal University of Minas Gerais (UFMG) for financial support in conducting this study. UFMG had no involvement in the study design, in the collection, analysis and interpretation of data, in the writing of the manuscript; and in the decision to submit the manuscript for publication.

References (22)

T. Ozcelik et al.
Auditory nerve–brainstem responses in cystic fibrosis patients
Int. J. Pediatr. Otorhinolaryngol.
(1996)
A.G. Cheng et al.
Sensorioneural hearing loss in patients with cystic fibrosis
Otolaryngol. Head Neck Surg.
(2009)
O.B. Piltcher et al.
The prevalence of neurosensorial hearing loss among cystic fibrosis patients from Hospital de Clinicas de Porto Alegre
Int. J. Pediatr. Otorhinolaryngol.
(2003)
M. Sone et al.
Loss of spiral ganglion cells as primary manifestation of aminoglycoside ototoxicity
Hear. Res.
(1998)
K.H. Chan
Sensorioneural hearing loss in children
Otolaryngol. Clin. N. Am.
(1994)
A.M. Brown et al.
Acoustic distortion products can be used to monitor the effects of chronic gentamicin treatment
Hear. Res.
(1989)
L.M. Aitken et al.
Cystic fibrosis
Dis. Month
(1993)
J. Haddad et al.
Ear disease in children with cystic fibrosis
Arch. Otolaryngol. Head Neck Surg.
(1994)
M. Jorrisen et al.
Middle ear disease in cystic fibrosis
Int. J. Pediatr. Otorhinolaryngol.
(1998)
B.P. Kimberley et al.
Measuring human cochlear traveling wave delay using distortion product emissions phase responses
J. Acoust. Soc. Am.
(1993)

M. Mulheran et al.

Comparison of distortion product OAE generation between a patient group requiring frequent gentamicin therapy and control subjects

Br. J. Audiol.

(1997)

Cited by (20)

Hearing thresholds at high frequency in patients with cystic fibrosis: a systematic review
2017, Brazilian Journal of Otorhinolaryngology
Citation Excerpt :
Other factors related to hearing loss, such as prematurity and history of intrauterine infection, in addition to AGs use, could contribute to a higher prevalence of hearing loss in the group that did not received AGs. Two studies in this review suggested that the use of AGs is not the only causal factor for hearing loss in CF.23,29 According to Al-Malky et al. (2011)23 the occurrence of hearing loss has been associated with high exposure to AGs; however, the high exposure resulted in hearing loss in a minority of patients. According to the authors of this study, genetic analysis may help explain the dichotomy found in response to GAs.
High-frequency audiometry may contribute to the early detection of hearing loss caused by ototoxic medications. Many ototoxic drugs are widely used in the treatment of patients with cystic fibrosis. Early detection of hearing loss should allow known harmful drugs to be identified before the damage affects speech frequencies. The damage caused by ototoxicity is irreversible, resulting in important social and psychological consequences. In children, hearing loss, even when restricted to high frequencies, can affect the development of language.
To investigate the efficacy and effectiveness of hearing monitoring through high-frequency audiometry in pediatric patients with cystic fibrosis.
Electronic databases PubMed, MedLine, Web of Science and LILACS were searched, from January to November 2015. The selected studies included those in which high-frequency audiometry was performed in patients with cystic fibrosis, undergoing treatment with ototoxic drugs and published in Portuguese, English and Spanish. The GRADE system was chosen for the evaluation of the methodological quality of the articles.
During the search process carried out from January 2015 to November 2015, 512 publications were identified, of which 250 were found in PubMed, 118 in MedLine, 142 in Web of Science and 2 in LILACS. Of these, nine articles were selected.
The incidence of hearing loss was identified at high frequencies in cystic fibrosis patients without hearing complaints. It is assumed that high-frequency audiometry can be an early diagnostic method to be recommended for hearing investigation of patients at risk of ototoxicity.
A audiometria de altas frequências pode contribuir para a detecção precoce de alterações auditivas causadas por medicações ototóxicas. No tratamento dos pacientes com fibrose cística, existem muitos fármacos ototóxicos amplamente utilizados. A detecção precoce de alterações auditivas deve permitir que sejam identificadas antes que o dano atinja as frequências da fala. A lesão causada pela ototoxicidade é irreversível, traz importantes consequências sociais e psicológicas. Nas crianças, a perda auditiva, mesmo restrita às altas frequências, pode afetar o desenvolvimento da linguagem.
Investigar a eficácia e a efetividade do monitoramento da audição por meio da audiometria de altas frequências em pacientes pediátricos com fibrose cística.
Foram consultadas as bases de dados eletrônicas PubMed, Medline, Web of Science e Lilacs, de janeiro a novembro de 2015. Foram selecionados os estudos em que foi feita audiometria de altas frequências em pacientes com fibrose cística em tratamento com medicamentos ototóxicos e publicados em português, inglês e espanhol. Para a avaliação da qualidade metodológica dos artigos optou-se pela utilização do Sistema Grade.
No processo de busca feito de janeiro de 2015 a novembro de 2015 foram encontradas 512 publicações, sendo 250 na PubMed, 118 na Medline, 142 na Web of Science e dois na Lilacs. Desses, foram selecionados nove artigos.
Identificou-se a ocorrência de perda auditiva em altas frequências em pacientes com fibrose cística sem queixas auditivas. Admite-se que audiometria em altas frequências possa ser um método de diagnóstico precoce a ser recomendado para investigação auditiva de pacientes em risco de ototoxicidade.
The cumulative effects of intravenous antibiotic treatments on hearing in patients with cystic fibrosis
2017, Journal of Cystic Fibrosis
Citation Excerpt :
These findings and factors suggest that it is imperative to routinely monitor hearing in any patient receiving IV-AG treatments. To date, there are few studies that have addressed the association of age, degree of hearing loss and dosage of IV-AG (± vancomycin) with cochleotoxicity in a large cohort of patients [1,4,9,17]. The present study is unique in that the above factors were investigated using a method that quantifies cumulative IV-antibiotic dose exposure and a separate method that takes into account the daily dosing schedule during these treatments (weighted).
Aminoglycosides (AGs) and glycopeptides are antibiotics essential for treating life-threatening respiratory infections in patients with cystic fibrosis (CF). The goal of this study was to examine the effects of cumulative intravenous (IV)-AG (amikacin and/or tobramycin) and/or glycopeptide (vancomycin) dosing on hearing status in patients with CF.
Hearing thresholds were measured from 0.25 to 16.0 kHz, in 81 participants with CF. Participants were categorized into two groups: normal hearing in both ears (≤ 25 dB HL for all frequency bands) or hearing loss (> 25 dB HL for any frequency band in either ear). Participants were also characterized into quartiles by their cumulative IV-AG (with or without vancomycin) exposure. Dosing was calculated using two strategies: (i) total number of lifetime doses, and (ii) total number of lifetime doses while accounting for the total doses per day. This was referred to as the “weighted” method.
Participants in the hearing loss group were significantly older than those in the normal-hearing group. After adjusting for gender and age at the time of hearing test, participants in the two highest-quartile exposure groups were almost 5 X more likely to have permanent sensorineural hearing loss than those in the two lowest-quartile exposure groups. There was a small group of CF patients who had normal hearing despite high exposure to IV-antibiotics.
Cumulative IV-antibiotic dosing has a significant negative effect on hearing sensitivity in patients with CF, when controlling for age and gender effects. A trend for increasing odds of hearing loss was associated with increasing cumulative IV-antibiotic dosing.
D-Methionine reduces tobramycin-induced ototoxicity without antimicrobial interference in animal models
2016, Journal of Cystic Fibrosis
Citation Excerpt :
Our current findings suggest d-met affords highly significant (p ≤ 0.01) otoprotection from tobramycin and shows promise for improving quality of life outcomes for patients receiving high dose or repeated tobramycin treatments. Tobramycin- and aminoglycoside-induced ototoxicity reports range from nearly absent to approximately 35% of cystic fibrosis patients [3,17,33,37,48,54,55,60,65] with an increased risk of aminoglycoside-induced hearing loss with repeated and higher cumulative doses. The majority of adolescent and adult cystic fibrosis patients are colonized with P. aeruginosa [23].
Tobramycin is a critical cystic fibrosis treatment however it causes ototoxicity. This study tested d-methionine protection from tobramycin-induced ototoxicity and potential antimicrobial interference.
Auditory brainstem responses (ABRs) and outer hair cell (OHC) quantifications measured protection in guinea pigs treated with tobramycin and a range of d-methionine doses.
In vitro antimicrobial interference studies tested inhibition and post antibiotic effect assays. In vivo antimicrobial interference studies tested normal and neutropenic Escherichia coli murine survival and intraperitoneal lavage bacterial counts.
d-Methionine conferred significant ABR threshold shift reductions. OHC protection was less robust but significant at 20 kHz in the 420 mg/kg/day group.
In vitro studies did not detect d-methionine-induced antimicrobial interference. In vivo studies did not detect d-methionine-induced interference in normal or neutropenic mice.
d-Methionine protects from tobramycin-induced ototoxicity without antimicrobial interference. The study results suggest d-met as a potential otoprotectant from clinical tobramycin use in cystic fibrosis patients.
Does amikacin treatment cause subclinical hearing loss in patients with cystic fibrosis?
2016, Toxicology Reports
Citation Excerpt :
Whereas former studies conducted with PTA had detected SNHL rates of up to 6% [4,5,9], more recent studies conducted with newer, more sensitive techniques such as high frequency PTA, DPOAE and ABR demonstrated higher prevalences, especially if patients had been given AGs repeatedly [14,15]. Studies demonstrate that AG ototoxicity is directly correlated with the number of treatment courses, hence the cumulative dose [10,13,17]. One recent systematic review including twelve studies conducted between 1979 and 2014 reported an overall SNHL prevalence of 0–29% in CF children treated with aminoglycosides; this was increased to 44% if the number of treatment courses was more than 10 [18].
Aminoglycosides (AGs) have been widely used for potential life-threatening bacterial infections. Although AGs are well known for their ototoxic side effects, some AGs such as amikacin are considered less harmful to auditory functions; thus, auditory monitoring is mostly neglected during treatment with these drugs.
To reflect the potential auditory hazards of repeated amikacin use on the patients with cystic fibrosis (CF).
32CF patients with prior exposure to at least 3 courses of amikacin (the CF group) and 35 non-CF patients visiting the outpatient clinic with any complaint other than hearing loss and no history of treatment with any AG(the control, or C group) were compared with pure-tone audiometry(PTA). The diagnosis of CF was made by Nanoduck sweat test.
The average age of the participants were 8.25 ± 2.76 years in the CF group and 8.58 ± 2.00 years in the C group (ranging from 5 to 13 years). 29 (43.28%) of the cases were female and 38 (56.71%) were male. Clinical SNHL(sensorineural hearing loss) was detected in 4 of the 32 subjects in the CF group. None of the subjects in the C group exhibited clinical SNHL. There was no statistically significant difference between the groups with regard to presence or absence of clinical SNHL (p > 0.05). However, hearing levels of the CF group were around 20 dB(decibel) HL(hearing loss), whereas hearing levels of the C group were around 5 dB. This difference was statistically significant for the pure tone averages of both all frequencies and speech frequencies (p < 0.05).
Repetitive exposure to AGs can cause permanent, although mild, sensorineural hearing loss. For prevention, hearing status of the patient should be closely monitored and treatment of choice should be precisely tailored according to the audiological evaluation. This is especially important in patients with CF who frequently experience medical conditions necessitating AGs use.
High frequency hearing thresholds and product distortion otoacoustic emissions in cystic fibrosis patients
2015, Brazilian Journal of Otorhinolaryngology
The treatment of patients with cystic fibrosis involves the use of ototoxic drugs, mainly aminoglycoside antibiotics. Due to the use of these drugs, fibrocystic patients are at risk of developing hearing loss.
To evaluate the hearing of patients with cystic fibrosis by High Frequency Audiometry and Distortion Product Otoacoustic Emissions.
Cross-sectional study. The study group consisted of 39 patients (7–20 years of age) with cystic fibrosis and a control group of 36 individuals in the same age group without otologic complaints, with normal audiometric thresholds and type A tympanometric curves. High Frequency Audiometry and Distortion Product Otoacoustic Emissions tests were conducted.
The study group had significantly higher thresholds at 250, 1000, 8000, 9000, 10,000, 12,500, and 16,000 Hz (p = 0.004) as well as higher prevalence of otoacoustic emission alterations at 1000 and 6000 Hz (p = 0.001), with significantly lower amplitudes at 1000, 1400, and 6000 Hz. There was a significant association between alterations in hearing thresholds in High Frequency Audiometry with the number of courses of aminoglycosides administered (p = 0.005). Eighty-three percent of patients who completed more than ten courses of aminoglycosides had hearing loss in High Frequency Audiometry.
A significant number of patients with cystic fibrosis who received repeated courses of aminoglycosides showed alterations in High Frequency Audiometry and Distortion Product Otoacoustic Emissions. The implementation of ten or more aminoglycoside cycles was associated with alterations in High Frequency Audiometry.
O tratamento dos pacientes com fibrose cística envolve o uso de medicamentos ototóxicos, principalmente de antibióticos aminoglicosídeos. Devido ao uso destes medicamentos, os pacientes fibrocísticos apresentam risco de desenvolver perda auditiva.
Avaliar a audição dos pacientes com fibrose cística pela Audiometria de Altas Frequências (AAF) e Emissões Otoacústicas por Produto de Distorção (EOAPD).
Estudo transversal. O grupo de estudo foi constituído por 39 pacientes com idades entre 7 e 20 anos com fibrose cística e o grupo controle por 36 indivíduos da mesma faixa etária, sem queixas otológicas, com limiares audiométricos normais e curvas timpanométricas tipo A. Foram realizados os exames de audiometria de altas frequências e emissões otoacústicas por produto de distorção.
O grupo de estudo apresentou limiares significativamente mais elevados em 250; 1000; 8.000; 9.000; 10.000; 12.500 e 16.000 Hz; (p = 0,004) e maior prevalência de alterações nas emissões otoacústicas em 1.000 e 6.000 Hz (p = 0,001); com amplitudes significativamente mais baixas em 1.000; 1.400 e 6.000 Hz. Houve associação significativa entre as alterações dos limiares auditivos na AAF com o número de ciclos de aminoglicosídeos realizados (p = 0,005). Oitenta e três por cento dos pacientes que foram submetidos a mais de 3 ciclos de aminoglicosídeos apresentaram perda auditiva na AAF.
Um número significativo de pacientes com fibrose cística que receberam repetidos ciclos de aminoglicosídeos apresentou alterações na AAF e EOAPD. A realização de 10 ou mais ciclos de aminoglicosídeos esteve associada às alterações na AAF.
High-frequency audiometry reveals high prevalence of aminoglycoside ototoxicity in children with cystic fibrosis
2015, Journal of Cystic Fibrosis
Citation Excerpt :
Standard pure tone audiometry (PTA) was the method used by most centers. To monitor hearing function for ototoxicity, two procedures have shown increased sensitivity for the early detection of ototoxic drug-induced hearing loss: extended high-frequency (EHF) pure tone audiometry [1,7,8] and distortion-product otoacoustic emissions (DPOAE) [3]. These tests are not widely used in CF patients, with standard PTA being used instead [1,9,10].
Intravenous aminoglycoside (IV AG) antibiotics, widely used in patients with cystic fibrosis (CF), are known to have ototoxic complications. Despite this, audiological monitoring is not commonly performed and if performed, uses only standard pure-tone audiometry (PTA). The aim of this study was to investigate ototoxicity in CF children, to determine the most appropriate audiological tests and to identify possible risk factors.
Auditory assessment was performed in CF children using standard pure tone audiometry (PTA), extended high-frequency (EHF) audiometry and distortion-product otoacoustic emissions (DPOAE).
70 CF children, mean (SD) age 10.7 (3.5) years, were recruited. Of the 63 children who received IV AG, 15 (24%) children had ototoxicity detected by EHF audiometry and DPOAE. Standard PTA only detected ototoxicity in 13 children. Eleven of these children had received at least 10 courses of IV AG courses. A 25 to 85 dB HL hearing loss (mean ± SD: 57.5 ± 25.7 dB HL) across all EHF frequencies and a significant drop in DPOAE amplitudes at frequencies 4 to 8 kHz were detected. However, standard PTA detected a significant hearing loss (> 20 dB HL) only at 8 kHz in 5 of these 15 children and none in 2 subjects who had significantly elevated EHF thresholds. The number of courses of IV AG received, age and lower lung function were shown to be risk factors for ototoxicity.
CF children who had received at least 10 courses of IV AG had a higher risk of ototoxicity. EHF audiometry identified 2 more children with ototoxicity than standard PTA and depending on facilities available, should be the test of choice for detecting ototoxicity in children with CF receiving IV AG.

View all citing articles on Scopus

View full text

Hearing loss in cystic fibrosis

Abstract

Objectives

Methods

Results

Conclusion

Introduction

Section snippets

Objectives

Patients

Study design

General sample characteristics

Aminoglycosides and ototoxicity assessment

Conclusion

Acknowledgements

Int. J. Pediatr. Otorhinolaryngol.

Otolaryngol. Head Neck Surg.

Int. J. Pediatr. Otorhinolaryngol.

Hear. Res.

Otolaryngol. Clin. N. Am.

Hear. Res.

Cystic fibrosis

Dis. Month

Ear disease in children with cystic fibrosis

Arch. Otolaryngol. Head Neck Surg.

Middle ear disease in cystic fibrosis

Int. J. Pediatr. Otorhinolaryngol.

Measuring human cochlear traveling wave delay using distortion product emissions phase responses

J. Acoust. Soc. Am.

Comparison of distortion product OAE generation between a patient group requiring frequent gentamicin therapy and control subjects

Br. J. Audiol.